Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a co-packaged combination kit containing **Esomeprazole** (a proton pump inhibitor), **Amoxicillin** (a penicillin antibiotic), and **Clarithromycin** (a macrolide antibiotic). It is designed for the eradication of *Helicobacter pylori*.
## Primary Indications
Treatment of *H. pylori* infection to reduce the risk of duodenal ulcer recurrence.
## Adult Dosing
* **Regimen:** 1 Esomeprazole 40mg capsule, 1 Amoxicillin 500mg capsule, and 1 Clarithromycin 500mg tablet taken together twice daily (morning and evening).
* **Duration:** 10 to 14 days.
* **Maximum:** Do not exceed the prescribed twice-daily dosing schedule to avoid antibiotic toxicity.
## Pediatric Dosing
Safety and efficacy have not been established in patients under 18 years. Use is generally avoided in pediatrics due to the specific combination packaging.
## Dose Adjustments
* **Renal Impairment:** Not recommended for patients with severe renal impairment (CrCl <30 mL/min) due to the Amoxicillin and Clarithromycin components.
* **Hepatic Impairment:** Use caution; Clarithromycin metabolism is heavily hepatic-dependent. No specific adjustment guidelines provided for the kit; monitor closely.
## Contraindications
* Known hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any component of the penicillins/macrolides.
* Concomitant use of pimozide, astemizole, terfenadine, cisapride, or ergot alkaloids due to risk of serious arrhythmias.
* History of cholestatic jaundice or hepatic dysfunction with macrolide use.
## Adverse Effects
* **Common:** Diarrhea, dysgeusia (taste disturbance), nausea, abdominal pain, headache, and dizziness.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis, DRESS syndrome, Stevens-Johnson syndrome), and QTc prolongation.
## Key Drug Interactions
* **CYP3A4 Substrates:** Clarithromycin is a potent CYP3A4 inhibitor; co-administration increases concentrations of statins (e.g., simvastatin, atorvastatin), benzodiazepines, and oral anticoagulants (monitor INR).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **Digoxin:** Clarithromycin may increase digoxin levels; monitor for toxicity.
## Monitoring
* **Signs of Infection:** Monitor for worsening symptoms or the development of *C. difficile* (persistent watery diarrhea).
* **Cardiac:** Monitor ECG if the patient is at risk for QTc prolongation or concurrently using other QT-prolonging agents.
* **Renal/Hepatic:** Periodic clearance/enzyme monitoring if therapy extends beyond 14 days (not recommended).
## Clinical Pearls
* **Administration:** Esomeprazole should be taken at least 60 minutes before a meal. Swallow capsules whole; do not crush or chew.
* **Adherence:** High rates of antibiotic resistance require strict adherence to the full 10–14 day course to ensure eradication.
* **Secondary Prevention:** If symptoms persist post-therapy, suggest diagnostic testing (urea breath test or stool antigen) to confirm eradication failure before retreating.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify dosing and drug interactions against current local prescribing guidelines, institutional protocols, and the official manufacturer's summary of product characteristics before prescribing or administering medication.
